Beam Therapeutics (BEAM) AGM 2026 summary

Opening remarks and agenda

• CEO welcomed attendees and highlighted the benefits of a virtual meeting format for inclusivity and efficiency.

• Attendees were introduced to the board members and the independent auditor from Deloitte.

• The agenda and rules of procedure were made available to shareholders via the web portal.

Board and executive committee updates

• Three Class III directors—John Evans, John Maraganore, and Christi Shaw—were nominated for terms ending in 2029.

Shareholder proposals

• Three proposals were presented: election of directors, ratification of Deloitte as auditor, and advisory approval of executive compensation.

• The board recommended voting in favor of all proposals.